Jun 9, 2019

The gene therapy revolution is here. Medicine is scrambling to keep pace

Posted by in categories: biotech/medical, genetics

Greg Dore at the Kirby Institute of NSW participated in Australia’s Hepatitis C pricing discussions, and believes our model will work for the new gene therapy drugs – notwithstanding their eye-popping price tags – and the fact that the patient populations for these rare genetic diseases will be tiny.

However, the real reason companies are getting into gene therapy is not just to treat rare disease. It’s because they realise this technology will be a game changer for medicine.

Read more

Comments are closed.